Genovis AB will hold its Annual General Meeting of Shareholders at 5:00 p.m. on Thursday, May 17, 2018 at Scheelevägen 2 (Medicon Village) in Lund. Participants may register upon arrival at the reception desk by the main entrance.

4:30 p.m. – 4:50 p.m. Registration        

5:00 pm Annual General Meeting convened

Right to participate. Registration

Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on May 11, 2018 and who have notified the company of their intention to attend the Annual General Meeting by no later than May 11, 2018, preferably before 3:00 p.m., have the right to attend the Annual General Meeting. Notification may be made by mail at Genovis AB (publ), Box 790, S-220 07 Lund, Sweden, by phone +46 (0)46-10 12 30, by fax +46 (0)46-12 80 20 or by email: Upon notification, shareholders must provide their name/company name, personal identity number/corporate identity number, address and phone number. Information about the number of assistants (maximum two) that the shareholder intends to bring to the meeting should also be included.

Shareholders who are represented by proxy shall issue a written, signed and dated power of attorney for the proxy. Shareholders should submit the power of attorney together with the notification of their intention to participate at the AGM. The expiry date of the proxy document may be no more than five years from its issue. Proxy forms are available on the company’s website, Representatives of legal entities must present a copy of the certificate of registration or equivalent authorization documents showing the authorized signatory.

Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to attend the meeting, request that their nominee re-register their shares in their own name, so that the shareholder is registered in the shareholder register on May 11, 2018. Such registration may be temporary.

Proposed Agenda

1. Opening of the Meeting.

2. Election of Chairman of the Meeting.

3. Preparation and approval of voting list.

4. Approval of the agenda

5. Election of individuals to verify the minutes.

6. Consideration of whether the meeting had been duly convened.

7. Presentation of the annual report and audit report, as well as the consolidated accounts and audit report for the Group.

8. Speech by the Chief Executive Officer, after which shareholders will have the opportunity to ask questions of the CEO, the Chairman of the Board and the auditor.

9. Resolutions on:

a)  adoption of the Income Statement and the Balance Sheet, as well as the Consolidated Income Statement and the Consolidated Balance Sheet,

b)  allocation of the Company's result in accordance with the adopted balance sheet,

c)  discharge from liability to the company of the Directors and the Chief Executive Officer.

10. Resolution regarding number members of the Board and deputy members.

11. Resolution regarding from directors’ fees.

12. Election of Directors and Chairman of the Board. 

13. Resolution on fees to auditors.

14. Appointment of members to the Nomination Committee and adoption of guidelines for the Nomination Committee

15. Resolution on the Board of Directors’ proposal for remuneration guidelines for senior executives

16. Resolution authorizing the Board of Directors to decide on the issuance of shares.

17. Authorization of the Chief Executive Officer to make such formal adjustments to the resolutions as may be necessary in conjunction with registration and implementation thereof.

18. Adjournment.

Item 15 The Board of Directors’ proposal for a motion regarding remuneration guidelines for senior executives  

The Board of Directors proposes that the AGM adopts the following guidelines for remuneration to senior executives. These guidelines are valid for employment agreements entered into after the guidelines are approved by the AGM, and for amendments made afterward to existing employment agreements. The basic principle is that remuneration and other terms of employment for the management and CEO will be competitive to ensure that Genovis AB can attract and retain senior executives.

Fixed remuneration policy 

The fixed remuneration to the management and the Chief Executive Officer should be competitive and be based on the individual areas of responsibility and performance.

Variable remuneration policy 

Incentive-based remuneration will be limited and linked to predetermined measurable criteria designed to promote long-term value creation for the Company. Variable compensation may not exceed a maximum of 25% percent of the fixed salary and will be set per fiscal year. 

The Board will consider on a yearly basis whether or not to propose a share-related or market value-related incentive program to the Annual General Meeting. The Annual General Meeting makes the decisions regarding such incentive programs.

Conditions for non-monetary benefits, pensions, termination, and severance pay 


Management and the CEO are entitled to a defined-contribution pension.

Termination and severance pay 

For the CEO the notice period is 6 months for the company and 6 months for the individual. For management personnel the notice period is 6 months for the Company and 3 months for the individual. Moreover, assuming that the Company gave notice of termination, in certain cases the CEO may be offered 12 months of severance pay.

The Company's undertaking in relation to senior executives and the chief executive may amount to a maximum of SEK 2.573.861.

The Board of Directors may depart from these guidelines if there are particular reasons in an individual case.

Item 16 The Board’s proposal authorizing the Board of Directors to decide on the issuance of shares. 

The Board proposes that the Meeting authorize the Board, on one or more occasions until the next annual meeting, with or without preferential rights for shareholders, to issue new shares, convertible bonds or warrants. New shares may be paid for in cash and/or in kind or set-off or on other terms. This decision would mean that the share capital is increased up to a maximum total of SEK 1,625,000 through the issuance of a maximum total of 6,500,000 shares at full subscription. When deciding on issuances without preferential rights for shareholders, the subscription shall be market-based at the time of the issue resolution. 

The reason for the possible deviation from shareholders’ preferential rights is to broaden the ownership group, acquire, or facilitate the raising of capital, increase the liquidity of shares, carry out acquisitions, or procure or permit the raising of capital for acquisitions.  

For a valid resolution under this item, the Meeting's resolution must be supported by shareholders representing at least two thirds of both the voting rights and the shares represented at the Meeting. 


The annual report, audit report, articles of association, proxy forms, and other proposals will be available at the Company's office at Scheelevägen 2, Box 790, S-220 07 Lund, Sweden, and on the Company’s website as of April 26, 2018, and will be sent, upon request, to shareholders who provide their mailing address.

Number of shares and votes 

At the time of issuance of this notice, the total number of shares and votes in the company is 60.294.162. 

Information at the Annual General Meeting 

Shareholders are reminded of their right to request information from the Board of Directors and the Chief Executive Officer pursuant to Chapter 7, sections 32 and 57 of the Swedish Companies Act.

Lund, April 2018

Genovis AB (publ.)  

Board of Directors 

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233


Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser. T: +46 (0)8-463 83 00.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the contact person set out above, on April 5, 2018.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North


Documents & Links